The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient's samples

European Journal of Cancer

Volumn 50, Issue 1, 2014, Pages 159-169

  Camara Clayette, V ^a   Lecluse, Y ^b   Schrader, C ^c   Klapper, W ^d   Vainchenker, W ^a   Hermine, O ^e   Ribrag, V ^a,b  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Biomarker; Mantle cell lymphoma; NF B; Prognosis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; SYNAPTOTAGMIN I;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; EPSTEIN BARR VIRUS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MANTLE CELL LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; WESTERN BLOTTING;

BIOMARKER; MANTLE CELL LYMPHOMA; NF-ΚB; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; NF-KAPPA B; TUMOR MARKERS, BIOLOGICAL;

EID: 84891627509     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.09.010     Document Type: Article

References (42)

1. E. Claudio, K. Brown, and U. Siebenlist NF-kappaB guides the survival and differentiation of developing lymphocytes Cell Death Differ 13 2006 697 701
2. R. Gugasyan, R. Grumont, and M. Grossmann et al. Rel/NF-kappaB transcription factors: key mediators of B-cell activation Immunol Rev 176 2000 134 140
3. R. Sen Control of B lymphocyte apoptosis by the transcription factor NF-kappaB Immunity 25 2006 871 883
4. U. Siebenlist, K. Brown, and E. Claudio Control of lymphocyte development by nuclear factor-kappaB Nat Rev Immunol 5 2005 435 445
5. E. Dejardin The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development Biochem Pharmacol 72 2006 1161 1179
6. P. Jares, D. Colomer, and E. Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nat Rev Cancer 7 2007 750 762
7. L.V. Pham, A.T. Tamayo, L.C. Yoshimura, P. Lo, and R.J. Ford Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis J Immunol 171 2003 88 95
8. J. Adams The proteasome: structure, function, and role in the cell Cancer Treat Rev 29 Suppl. 1 2003 3 9
9. Y. Dai, X.Y. Pei, M. Rahmani, D.H. Conrad, P. Dent, and S. Grant Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells Blood 103 2004 2761 2770
10. X. Hu, W.E. Janssen, and L.C. Moscinski et al. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent. NF-kappaB-independent mechanism Cancer Res 61 2001 6290 6296
11. P. Pérez-Galan, G. Roué, N. Villamor, E. Montserrat, E. Campo, and D. Colomer The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status Blood 107 2006 257 264
12. J.W. Pierce, R. Schoenleber, and G. Jesmok et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo J Biol Chem 272 1997 21096 21103
13. R. M'Kacher, F. Farace, and A. Bennaceur-Griscelli et al. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model Cancer Genet Cytogenet 143 2003 32 38
14. K. Brown, S. Gerstberger, L. Carlson, G. Franzoso, and U. Siebenlist Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation Science 267 1995 1485 1488
15. C. Schrader, P. Meusers, and G. Brittinger et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome Leukemia 18 2004 1200 1206
16. M. Tiemann, A. Teymoortash, and C. Schrader et al. Chronic sclerosing sialadenitis of the submandibular gland is mainly due to a T lymphocyte immune reaction Mod Pathol 15 2002 845 852
17. E.D. Cahir-McFarland, K. Carter, and A. Rosenwald et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells J Virol 78 2004 4108 4119
18. K.M. Izumi, and E.D. Kieff The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB Proc Natl Acad Sci USA 94 1997 12592 12597
19. P. Busson, R.H. Edwards, T. Tursz, and N. Raab-Traub Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene J Gen Virol 76 Pt 1 1995 139 145
20. I. Salaverria, P. Perez-Galan, D. Colomer, and E. Campo Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives Haematologica 91 2006 11 16
21. J.A. Brockman, D.C. Scherer, and T.A. McKinsey et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation Mol Cell Biol 15 1995 2809 2818
22. G. Brittinger, H. Bartels, and H. Common et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel lymphoma study group Hematol Oncol 2 1984 269 306
23. P. Meusers, M. Engelhard, and H. Bartels et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis Hematol Oncol 7 1989 365 380
24. C.Y. Sasaki, T.J. Barberi, P. Ghosh, and D.L. Longo Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway J Biol Chem 280 2005 34538 34547
25. G. Roue, P. Perez-Galan, M. Lopez-Guerra, N. Villamor, E. Campo, and D. Colomer Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level J Immunol 178 2007 1923 1930
26. G. Goormachtigh, T.S. Ouk, and A. Mougel et al. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways J Virol 80 2006 7382 7393
27. J.A. Herrero, P. Mathew, and C.V. Paya LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha J Virol 69 1995 2168 2174
28. K.M. Kaye, O. Devergne, and J.N. Harada et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein Proc Natl Acad Sci USA 93 1996 11085 11090
29. S. Tafuku, T. Matsuda, H. Kawakami, M. Tomita, H. Yagita, and N. Mori Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma Eur J Haematol 76 2006 64 74
30. D.T. Yang, K.H. Young, B.S. Kahl, S. Markovina, and S. Miyamoto Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma Mol Cancer 7 2008 40
31. C. Schrader, D. Janssen, and W. Klapper et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma Br J Cancer 93 2005 939 945
32. C. Schrader, D. Janssen, and P. Meusers et al. Repp86: a new prognostic marker in mantle cell lymphoma Eur J Haematol 75 2005 498 504
33. M. Tiemann, C. Schrader, and W. Klapper et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL network Br J Haematol 131 2005 29 38
34. S. Shishodia, H.M. Amin, R. Lai, and B.B. Aggarwal Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma Biochem Pharmacol 70 2005 700 713
35. Z.W. Li, and W.S. Dalton Tumor microenvironment and drug resistance in hematologic malignancies Blood Rev 20 2006 333 342
36. S. Cuni, P. Perez-Aciego, and G. Perez-Chacon et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells Leukemia 18 2004 1391 1400
37. T. Endo, M. Nishio, and T. Enzler et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway Blood 109 2007 703 710
38. C. Kern, J.F. Cornuel, and C. Billard et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway Blood 103 2004 679 688
39. A. Zaninoni, F.G. Imperiali, C. Pasquini, A. Zanella, and W. Barcellini Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia Exp Hematol 31 2003 185 190
40. R.E. Davis, K.D. Brown, U. Siebenlist, and L.M. Staudt Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells J Exp Med 194 2001 1861 1874
41. M. Compagno, W.K. Lim, and A. Grunn et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 459 2009 717 721
42. L. Pasqualucci, V. Trifonov, and G. Fabbri et al. Analysis of the coding genome of diffuse large B-cell lymphoma Nat Genet 43 2011 830 837